Litcius/Paper detail

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan

Daisuke Kanai, Hiromichi Wakui, Tatsuya Haze, Kengo Azushima, Sho Kinguchi, Shunichiro Tsukamoto, Tomohiko Kanaoka, Shingo Urate, Yoshiyuki Toya, Nobuhito Hirawa, Hideaki Kato, Fumimasa Watanabe, Kanako Hanaoka, Masaaki Hanaoka, Hiroshi Mitsuhashi, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura

2022Clinical and Experimental Nephrology14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)VirologySpike Protein2019-20 coronavirus outbreakVaccinationTiterAntibodyNephrologyCoronavirusImmunologyInternal medicineOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research Studies
SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan | Litcius